JP2019516805A - 認知症を予防又は緩和するための組成物 - Google Patents
認知症を予防又は緩和するための組成物 Download PDFInfo
- Publication number
- JP2019516805A JP2019516805A JP2019514700A JP2019514700A JP2019516805A JP 2019516805 A JP2019516805 A JP 2019516805A JP 2019514700 A JP2019514700 A JP 2019514700A JP 2019514700 A JP2019514700 A JP 2019514700A JP 2019516805 A JP2019516805 A JP 2019516805A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tocotrienol
- weight
- vitamin
- dementia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 206010012289 Dementia Diseases 0.000 title claims abstract description 44
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 34
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229930003802 tocotrienol Natural products 0.000 claims abstract description 24
- 239000011731 tocotrienol Substances 0.000 claims abstract description 24
- 235000019148 tocotrienols Nutrition 0.000 claims abstract description 24
- 239000011732 tocopherol Substances 0.000 claims abstract description 23
- 229930003799 tocopherol Natural products 0.000 claims abstract description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 22
- 229960001295 tocopherol Drugs 0.000 claims abstract description 22
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims abstract description 19
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims abstract description 19
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229940031439 squalene Drugs 0.000 claims abstract description 19
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 19
- 239000011720 vitamin B Substances 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 18
- -1 polyoxyethylene Polymers 0.000 claims description 17
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 claims description 14
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 10
- 239000008158 vegetable oil Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 235000013871 bee wax Nutrition 0.000 claims description 8
- 239000012166 beeswax Substances 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 229960003511 macrogol Drugs 0.000 claims description 8
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 7
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 claims description 7
- 229940064063 alpha tocotrienol Drugs 0.000 claims description 7
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 7
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 claims description 7
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 7
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 claims description 7
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims description 7
- 235000019145 α-tocotrienol Nutrition 0.000 claims description 7
- 239000011730 α-tocotrienol Substances 0.000 claims description 7
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 7
- 239000011723 β-tocotrienol Substances 0.000 claims description 7
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 7
- 235000019150 γ-tocotrienol Nutrition 0.000 claims description 7
- 239000011722 γ-tocotrienol Substances 0.000 claims description 7
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 claims description 7
- 235000019144 δ-tocotrienol Nutrition 0.000 claims description 7
- 239000011729 δ-tocotrienol Substances 0.000 claims description 7
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 claims description 7
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 6
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229930003761 Vitamin B9 Natural products 0.000 claims description 6
- 229940087168 alpha tocopherol Drugs 0.000 claims description 6
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 6
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 6
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960000984 tocofersolan Drugs 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019159 vitamin B9 Nutrition 0.000 claims description 6
- 239000011727 vitamin B9 Substances 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- 235000004835 α-tocopherol Nutrition 0.000 claims description 6
- 239000002076 α-tocopherol Substances 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 125000005907 alkyl ester group Chemical group 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920000223 polyglycerol Polymers 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229920002675 Polyoxyl Polymers 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 206010072731 White matter lesion Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000006984 memory degeneration Effects 0.000 description 3
- 208000023060 memory loss Diseases 0.000 description 3
- 208000027061 mild cognitive impairment Diseases 0.000 description 3
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000010482 CADASIL Diseases 0.000 description 1
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 240000003133 Elaeis guineensis Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000010577 Niemann-Pick disease type C Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 208000007930 Type C Niemann-Pick Disease Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 208000014670 posterior cortical atrophy Diseases 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本発明は、トコトリエノール、トコフェロール、スクアレン、及びBビタミンの混合物、並びに医薬的に許容される担体を含む、対象者の認知症を予防又は遅延するための組成物を開示する。具体的には、組成物は、対象者の認知症の発症を予防又は遅延することができる。用語「認知症」は、本明細書で使用するとき、脳疾患又は脳損傷によって引き起こされる慢性的かつ進行性の精神機能障害を指す。認知症は、以下の特徴の一部又は全てを含むがこれらに限定されない、脳機能の漸進的低下によって特徴付けられる:記憶喪失、言語障害、見当識障害、人格変化、日常生活困難、セルフネグレクト及び精神医学的症状。認知症は、原因及び疾患が多様であることから、多くの種類が存在し、その例としては、限定するものではないが、アルツハイマー病、血管性認知症、レビー小体型認知症、前頭側頭型認知症、ピック病、混合型認知症、パーキンソン病による認知症、クロイツフェルト・ヤコブ病、正常圧水頭症、ハンチントン病、ウェルニッケ・コルサコフ症候群、外傷性脳損傷、ダウン症候群、HIV関連神経認知障害、軽度認知障害、後部皮質萎縮症、大脳皮質基底核変性症、多発性硬化症、ニーマンピック病C型、進行性核上性麻痺、嗜銀顆粒病、皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症(CADASIL)、ビンスバンガー病、若年性認知症、多発梗塞性認知症及びアルコール性認知症が挙げられる。より具体的には、本明細書に開示される組成物は、記憶低下及び/又はその他の精神能力の予防、遅延又は緩和ができる。
Claims (16)
- トコトリエノール、トコフェロール、スクアレン、及びBビタミンの混合物、並びに医薬的に許容される担体を含む、対象者の認知症を予防又は緩和するための組成物。
- 蜜蝋、ブチル化ヒドロキシトルエン、又はその両方を更に含む、請求項1に記載の組成物。
- 前記トコトリエノールは、α−トコトリエノール、β−トコトリエノール、γ−トコトリエノール及びδ−トコトリエノールのうちいずれか1つ又は任意の組み合わせである、請求項1又は2に記載の組成物。
- 前記トコトリエノールは、組成物の15重量%〜35重量%の量で存在する、請求項1又は3に記載の組成物。
- 前記トコフェロールは、α−トコフェロールである、請求項1〜4のうちいずれか一項に記載の組成物。
- 前記トコフェロールは、組成物の3重量%〜9重量%の量で存在する、請求項1又は5に記載の組成物。
- 前記スクアレンは、植物から誘導される、請求項1〜6のうちいずれか一項に記載の組成物。
- 前記スクアレンは、組成物の1.0重量%〜5.0重量%の量で存在する、請求項1〜7のうちいずれか一項に記載の組成物。
- 前記Bビタミンは、ビタミンB6、ビタミンB9及びビタミンB12のうちいずれか1つ又は任意の組み合わせである、請求項1〜8のうちいずれか一項に記載の組成物。
- 前記Bビタミンは、組成物の0.5重量%〜10.5重量%の量で存在する、請求項1〜9のうちいずれか一項に記載の組成物。
- 前記医薬的に許容される担体は、植物性油、カプリロカプロイルマクロゴールグリセリド、ポリオキシエチレンヒマシ油若しくは誘導体、ポリソルベート、脂肪酸のポリグリセロールエステル、脂肪酸のスクロースエステル、ポリエチレンアルキルエステル、ポリオキシル40ステアレート及びリン脂質のうちいずれか1つ又は任意の組み合わせである、請求項1〜10のうちいずれか一項に記載の組成物。
- 前記医薬的に許容される担体は、組成物の24重量%〜80重量%の量で存在する、請求項1〜11のうちいずれか一項に記載の組成物。
- 4重量%〜11重量%のα−トコトリエノール、0.25重量%〜2重量%のβ−トコトリエノール、7重量%〜15重量%のγ−トコトリエノール、2.0重量%〜7重量%のδ−トコトリエノール、3重量%〜9重量%のα−トコフェロール、1.0重量%〜5.0重量%のスクアレン、0.5重量%〜10.0重量%のビタミンB6、0.01重量%〜0.1重量%のビタミンB9、0.01重量%〜0.1重量%のビタミンB12、及び24重量%〜80重量%の医薬的に許容される担体を含む、対象者の認知症を予防又は緩和するための組成物。
- 蜜蝋、ブチル化ヒドロキシトルエン、又はその両方を更に含む、請求項13に記載の組成物。
- 前記医薬的に許容される担体は、植物性油、カプリロカプロイルマクロゴールグリセリド、ポリオキシエチレンヒマシ油若しくは誘導体、ポリソルベート、脂肪酸のポリグリセロールエステル、脂肪酸のスクロースエステル、ポリエチレンアルキルエステル、ポリオキシル40ステアレート及びリン脂質のうちいずれか1つ又は任意の組み合わせである、請求項13又は14に記載の組成物。
- 対象者の認知症を予防又は緩和するための薬剤の製造における、請求項1〜15のうちいずれか一項に記載の組成物の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021084423A JP2021121613A (ja) | 2016-05-23 | 2021-05-19 | 認知症を予防又は緩和するための組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2016701846A MY192213A (en) | 2016-05-23 | 2016-05-23 | A composition for preventing or mitigating dementia |
MYPI2016701846 | 2016-05-23 | ||
PCT/MY2016/050046 WO2017204618A1 (en) | 2016-05-23 | 2016-08-17 | A composition for preventing or mitigating dementia |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021084423A Division JP2021121613A (ja) | 2016-05-23 | 2021-05-19 | 認知症を予防又は緩和するための組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2019516805A true JP2019516805A (ja) | 2019-06-20 |
Family
ID=60412508
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019514700A Pending JP2019516805A (ja) | 2016-05-23 | 2016-08-17 | 認知症を予防又は緩和するための組成物 |
JP2021084423A Pending JP2021121613A (ja) | 2016-05-23 | 2021-05-19 | 認知症を予防又は緩和するための組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021084423A Pending JP2021121613A (ja) | 2016-05-23 | 2021-05-19 | 認知症を予防又は緩和するための組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11357751B2 (ja) |
EP (1) | EP3463336A4 (ja) |
JP (2) | JP2019516805A (ja) |
KR (1) | KR20190016973A (ja) |
CN (1) | CN109715154A (ja) |
AU (1) | AU2016408304B2 (ja) |
MY (1) | MY192213A (ja) |
PH (1) | PH12018502496A1 (ja) |
SG (1) | SG11201810469TA (ja) |
WO (1) | WO2017204618A1 (ja) |
ZA (1) | ZA201808515B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023503087A (ja) * | 2019-11-19 | 2023-01-26 | ホヴィッド・ブルハド | 皮質下梗塞と白質脳症とを伴う常染色体優性脳動脈症(cadasil)を管理するためのビタミンeトコトリエノールを含有する組成物の使用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3468530A4 (en) | 2016-06-10 | 2020-03-11 | Clarity Cosmetics Inc. | NON-COMEDOGENOUS HAIR AND SCALP CARE FORMULATIONS AND METHOD OF USE |
JP7186442B2 (ja) * | 2019-04-22 | 2022-12-09 | 国立研究開発法人産業技術総合研究所 | 新規スクアレン誘導体および抗炎症剤 |
EP3831369A1 (en) * | 2019-12-03 | 2021-06-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Squalene for the treatment of demyelinating disorders |
AU2021283774A1 (en) * | 2020-06-04 | 2023-01-19 | Hovid Berhad | Composition for normalisation of fatty liver and method for producing the same |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435186A (zh) * | 2003-03-11 | 2003-08-13 | 刘威 | 精制海狗油在制备防治老年痴呆及中风后遗症药中的应用 |
JP2005245419A (ja) * | 2004-03-04 | 2005-09-15 | Hideyo Sasaya | 健康食品 |
US20090110745A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
JP2015524477A (ja) * | 2012-08-07 | 2015-08-24 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 神経機能を改善するための多成分製剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4326675C2 (de) * | 1993-08-09 | 1996-12-12 | Puetter Medice Chem Pharm | Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Vorbeugung von Nervendegenerationserkrankungen und Altersdementia |
US6716451B1 (en) * | 1999-11-30 | 2004-04-06 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US8586109B2 (en) * | 2003-04-10 | 2013-11-19 | American River Nutrition, Inc. | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
US20110201679A1 (en) * | 2004-05-14 | 2011-08-18 | Rubin Berish Y | Use of Tocotrienols for Elevating IKBKAP Gene Expression and Treating Neurodegenerative Diseases or Disorders |
WO2007034323A1 (en) * | 2005-09-26 | 2007-03-29 | Gerry Dean Freundl | Composition for use in treatment of hair balding, thinning and loss and method for same |
US20120148685A1 (en) * | 2009-06-10 | 2012-06-14 | Engergy4Life AG | Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders |
DE202011004360U1 (de) * | 2010-05-07 | 2011-06-09 | Tavarlin Ag, 64293 | Speiseöl |
ES2517741B1 (es) * | 2013-04-30 | 2015-09-09 | Lacer, S.A. | Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento |
FR3010906B1 (fr) * | 2013-09-25 | 2016-12-23 | Expanscience Lab | Extrait lipidique de graines de passiflores |
MY161634A (en) * | 2013-10-03 | 2017-04-28 | Malaysian Palm Oil Board | A method for producing high lipophilic antioxidants noodle products |
-
2016
- 2016-05-23 MY MYPI2016701846A patent/MY192213A/en unknown
- 2016-08-17 SG SG11201810469TA patent/SG11201810469TA/en unknown
- 2016-08-17 JP JP2019514700A patent/JP2019516805A/ja active Pending
- 2016-08-17 EP EP16903284.4A patent/EP3463336A4/en not_active Withdrawn
- 2016-08-17 WO PCT/MY2016/050046 patent/WO2017204618A1/en active Search and Examination
- 2016-08-17 CN CN201680087021.9A patent/CN109715154A/zh active Pending
- 2016-08-17 AU AU2016408304A patent/AU2016408304B2/en active Active
- 2016-08-17 KR KR1020187037196A patent/KR20190016973A/ko not_active Application Discontinuation
- 2016-08-17 US US16/304,248 patent/US11357751B2/en active Active
-
2018
- 2018-11-26 PH PH12018502496A patent/PH12018502496A1/en unknown
- 2018-12-18 ZA ZA2018/08515A patent/ZA201808515B/en unknown
-
2021
- 2021-05-19 JP JP2021084423A patent/JP2021121613A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1435186A (zh) * | 2003-03-11 | 2003-08-13 | 刘威 | 精制海狗油在制备防治老年痴呆及中风后遗症药中的应用 |
JP2005245419A (ja) * | 2004-03-04 | 2005-09-15 | Hideyo Sasaya | 健康食品 |
US20090110745A1 (en) * | 2007-10-31 | 2009-04-30 | University Of Massachusetts Lowell | Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging |
JP2015524477A (ja) * | 2012-08-07 | 2015-08-24 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 神経機能を改善するための多成分製剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023503087A (ja) * | 2019-11-19 | 2023-01-26 | ホヴィッド・ブルハド | 皮質下梗塞と白質脳症とを伴う常染色体優性脳動脈症(cadasil)を管理するためのビタミンeトコトリエノールを含有する組成物の使用 |
JP7467626B2 (ja) | 2019-11-19 | 2024-04-15 | ホヴィッド・ブルハド | 皮質下梗塞と白質脳症とを伴う常染色体優性脳動脈症(cadasil)を管理するためのビタミンeトコトリエノールを含有する組成物の使用 |
Also Published As
Publication number | Publication date |
---|---|
MY192213A (en) | 2022-08-08 |
KR20190016973A (ko) | 2019-02-19 |
US20200316017A1 (en) | 2020-10-08 |
EP3463336A4 (en) | 2020-03-25 |
PH12018502496A1 (en) | 2019-04-08 |
WO2017204618A1 (en) | 2017-11-30 |
EP3463336A1 (en) | 2019-04-10 |
ZA201808515B (en) | 2019-08-28 |
AU2016408304B2 (en) | 2022-04-07 |
US11357751B2 (en) | 2022-06-14 |
SG11201810469TA (en) | 2018-12-28 |
CN109715154A (zh) | 2019-05-03 |
AU2016408304A1 (en) | 2018-12-13 |
JP2021121613A (ja) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021121613A (ja) | 認知症を予防又は緩和するための組成物 | |
O’byrne et al. | Studies of LDL oxidation following α-, γ-, or δ-tocotrienyl acetate supplementation of hypercholesterolemic humans | |
US9511107B2 (en) | Phenolic compositions derived from apple skin and uses thereof | |
JP2020524151A (ja) | 睡眠障害組成物及びその治療 | |
AU2004259223A1 (en) | Anti-inflammatory formulations | |
US20120269868A1 (en) | Compositions and methods for nutritional supplementation | |
ES2889874T3 (es) | Tratamiento de neuropatía óptica y reducción del estrés oxidativo inducido por esteroides con sustancias polinsaturadas estabilizadas | |
JP2001507363A (ja) | イソプレノイド類とスタチン類との組合せによる腫瘍成長抑制方法 | |
KR20010040776A (ko) | 염증 상태의 치료방법 및 이를 위한 조성물 | |
US20080166419A1 (en) | Krill oil compositions | |
US20130017278A1 (en) | Composition and method for improving brain function | |
KR101430509B1 (ko) | 소양증 및 염증을 억제·완화하기 위한 의약 및 기능성 식품 | |
JP5226980B2 (ja) | HMG−CoAリダクターゼ阻害剤、トコフェロール類及びCoQ10を含有する医薬組成物 | |
US6207187B1 (en) | Compositions based on tocopherols | |
TWI810499B (zh) | 用於治療體顯性腦動脈血管病變合併皮質下腦梗塞及腦白質病變的組成物 | |
JP2005035975A (ja) | 治療 | |
WO1996019218A1 (en) | Tocopherol and tocotrienol compositions | |
WALSH | Heart Disease in Lupus:‘Startlingly’Worrisome | |
Manaf et al. | Plasma vitamin C and tocotrienols changes in response to dietary supplementation among young male adults | |
WO2006057209A1 (ja) | 血中遊離脂肪酸低下作用を有する医薬組成物 | |
Greg Arnold | Coenzyme Q10 May Help Protect Against Alzheimer Disease | |
US20080166418A1 (en) | Krill oil compositions | |
Kuzniarz | Cataracts and multivitamins | |
MX2007011835A (es) | Composiciones farmaceutica, proceso de preparacion de la referida composicion y uso de la misma. | |
JP2009126815A (ja) | 高尿酸血症の予防または改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190131 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200526 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210119 |